SALT LAKE CITY, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, announced today that it will release financial results for its fourth quarter and full year 2014 on Thursday, March 5, 2015, before the market opens.
Following the announcement, the Company will host a conference call and simultaneous audio webcast with Dr. Sonny Bal, Chairman and CEO of Amedica Corporation, as well as key members of the management team that same day to review its fourth quarter and fiscal year 2014 results. Details related to this call are as follows:
|Date:||Thursday, March 5, 2015|
|Time:||10:00 a.m. Eastern Time|
|Dial-in:||Toll-free (855) 455-6055|
|International (484) 756-4308|
|Webcast:||Investors section of the Company's website|
A telephone replay will be available for one week following the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants. When prompted, please enter the Conference ID number 85476438. For those who are not available to listen to the live webcast, the call will be archived on the investor relations section of the Amedica website under Events & Presentations.
About Amedica Corporation
Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility and, through its partnership with Kyocera, the world's largest ceramic manufacturer. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM partnerships.
For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.
CONTACT: Mike Houston Director of Investor Relations 801-839-3534 email@example.com